Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
adIVO: ivosidenib maintenance after standard adjuvant chemotherapy in resected IDH1-mutant intrahepatic cholangiocarcinoma
2024-520219-42-00Phase 3Authorised
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ivosidenib in intrahepatic cholangiocarcinoma (ICC), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: 1-year recurrence-free survival rate. Planned start Nov 2025; status: authorised.
02
Drugs
ivosidenib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2024-520219-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520219-42-00.